Head of Late Clinical Development, Oncology GPD at Pfizer, accountable for strategy across all oncology and hematology areas after a 20- year career in academic medical oncology. I transitioned to pharmaceutical industry as Vice President, Clinical Development Leader at Pfizer in 2019. Recognized around the world for expertise in personalized genomics-driven cancer therapies, immunotherapies, translational research and cancer chemoprevention. Joined Pfizer In September2019 from the University of Texas MD Anderson Cancer Center, where I was an Endowed Professor of Medicine and Section Chief of Thoracic Oncology in the Department of Thoracic/Head and Neck Medical Oncology. Have led numerous clinical and translational research projects focused on the development of biomarker-based targeted therapies to overcome therapeutic resistance in advanced disease., been a member of the FDA’s Oncologic Drugs Advisory Committee (ODAC) and have served as co-principal investigator on the Master Lung Protocol (Lung-MAP) study, a pioneering umbrella trial simultaneously testing multiple precision medicines in squamous cell lung cancer, supported by the National Cancer Institute and run through a unique and groundbreaking partnership between patient advocacy organizations, pharmaceutical companies (including Pfizer) and public institutions. Extensive experience leading the design and implementation of innovative clinical development programs in oncology, managing multidisciplinary research teams, and spearheading collaborative efforts within and across the global oncology community.